Skip to main content

Table 1 Baseline characteristics

From: Supraventricular arrhythmia, N-terminal pro-brain natriuretic peptide and troponin T concentration in relation to incidence of atrial fibrillation: a prospective cohort study

  All (n = 373) Men (n = 170) Women (n = 203)
Case of AF (n, %) 88 (23.6) 46 (27.1) 42 (20.7)
Age (years) 64.0 (5.9) 64.1 (6.1) 64.0 (5.7)
Current smoking (n, %) 85 (22.8) 45 (26.5) 40 (19.7)
History of diabetes (n, %) 32 (8.6) 18 (10.6) 14 (6.9)
History of coronary events (n, %) 8 (2.1) 5 (2.9) 3 (1.5)
History of heart failure (n, %) 2 (0.5) 1 (0.6) 1 (0.5)
Anti-hypertensive medication (n, %) 95 (25.5) 38 (22.4) 57 (28.1)
Systolic blood pressure (mmHg) 143.6 (18.5) 145.2 (18.6) 142.3 (18.3)
Diastolic blood pressure (mmHg) 88.3 (9.6) 90.3 (9.6) 86.6 (9.3)
Height (cm; n = 372) 169.0 (9.4) 176.3 (6.9) 162.8 (6.3)
Weight (kg; n = 372) 77.3 (13.2) 83.9 (12.2) 71.8 (11.4)
HOMA-IR (n = 366) 2.54 (1.83) 2.75 (2.03) 2.36 (1.64)
LDL (mmol/l; n = 372) 3.72 (0.83) 3.67 (0.76) 3.76 (0.89)
NT-proBNP (pg/ml) 41.84 (100.73) 53.22 (128.35) 32.32 (68.56)
Troponin T (pg/ml) 1.14 (1.40) 1.46 (1.66) 0.88 (1.07)
CHARGE-AF risk score (n = 372) 12.01 (0.75) 12.26 (0.73) 11.81 (0.71)
  1. Values are presented as mean (SD) or n (%)
  2. AF atrial fibrillation, HOMA-IR homeostasis model assessment of insulin resistance, LDL low-density lipoprotein, NT-proBNP N terminal pro B type natriuretic peptide